[
  {
    "ts": null,
    "headline": "Tracking Tweedy Browne Portfolio - Q2 2025 Update",
    "summary": "Tweedy Browneâs Q2 2025 portfolio reveals disciplined value investing with key holdings in CNH, Berkshire Hathaway, and Alphabet. See more here.",
    "url": "https://finnhub.io/api/news?id=e03c713ba631d609f2c49ccff7a742056cefa93b4a09a750ba29c0e3b62a041b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755124466,
      "headline": "Tracking Tweedy Browne Portfolio - Q2 2025 Update",
      "id": 136342725,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/953164652/image_953164652.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Tweedy Browneâs Q2 2025 portfolio reveals disciplined value investing with key holdings in CNH, Berkshire Hathaway, and Alphabet. See more here.",
      "url": "https://finnhub.io/api/news?id=e03c713ba631d609f2c49ccff7a742056cefa93b4a09a750ba29c0e3b62a041b"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=75bcc4d43257e60ea1eb8740dcf97324014a27d149de9e9f2c54a6f9d1cb610b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755103200,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 136388521,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=75bcc4d43257e60ea1eb8740dcf97324014a27d149de9e9f2c54a6f9d1cb610b"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=8dfe7bda1a2aa682eab72e75af5bb71fc1567d1346a24ef29720bd04fd020f6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755090003,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136339826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=8dfe7bda1a2aa682eab72e75af5bb71fc1567d1346a24ef29720bd04fd020f6f"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global AI in Synthetic Biology Market size & share revenue was valued at approximately USD 24.58 Billion in 2024 and is expected to reach USD 30.76 Billion in 2025 and is expected to reach around USD 192.95 Billion by 2034, at a CAGR of 28.63% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Ginkgo Bioworks, Am",
    "url": "https://finnhub.io/api/news?id=a9d4b27834c4a287d359e19e4d7c32379cd4380bb80d79efec2562426598b9ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755084600,
      "headline": "[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136328370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global AI in Synthetic Biology Market size & share revenue was valued at approximately USD 24.58 Billion in 2024 and is expected to reach USD 30.76 Billion in 2025 and is expected to reach around USD 192.95 Billion by 2034, at a CAGR of 28.63% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Ginkgo Bioworks, Am",
      "url": "https://finnhub.io/api/news?id=a9d4b27834c4a287d359e19e4d7c32379cd4380bb80d79efec2562426598b9ab"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call",
    "summary": "Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply negatively. Management pointed to strong commercial execution in its cystic fibrosis franchise, growing uptake of new therapies like ALYFTREK and JOURNAVX, and expanding momentum for CASGEVY in sickle cell disease and beta thalassemia. CEO Reshma Kewalramani highlighted that “momentum accelerated, and we executed with very strong performance across the board, growing and dive",
    "url": "https://finnhub.io/api/news?id=6465691fa312256a92168aa0f511a9066020b201217d90f758a1d363b149b026",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057671,
      "headline": "The 5 Most Interesting Analyst Questions From Vertex Pharmaceuticals’s Q2 Earnings Call",
      "id": 136328467,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply negatively. Management pointed to strong commercial execution in its cystic fibrosis franchise, growing uptake of new therapies like ALYFTREK and JOURNAVX, and expanding momentum for CASGEVY in sickle cell disease and beta thalassemia. CEO Reshma Kewalramani highlighted that “momentum accelerated, and we executed with very strong performance across the board, growing and dive",
      "url": "https://finnhub.io/api/news?id=6465691fa312256a92168aa0f511a9066020b201217d90f758a1d363b149b026"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=aabadff068cceab26529025cfb3394f87ddac22dad8bc36578142691c50634bc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057237,
      "headline": "VRTX Q2 2025 Deep Dive: New Product Launches and Pipeline Update in a Volatile Market",
      "id": 136328468,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 12.1% year on year to $2.96 billion. The company expects the full year’s revenue to be around $11.93 billion, close to analysts’ estimates. Its non-GAAP profit of $4.52 per share was 6.3% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=aabadff068cceab26529025cfb3394f87ddac22dad8bc36578142691c50634bc"
    }
  }
]